Welcome to LookChem.com Sign In|Join Free
  • or
ethyl (2S)-ethoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

696663-45-3

Post Buying Request

696663-45-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

696663-45-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 696663-45-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,6,6,6 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 696663-45:
(8*6)+(7*9)+(6*6)+(5*6)+(4*6)+(3*3)+(2*4)+(1*5)=223
223 % 10 = 3
So 696663-45-3 is a valid CAS Registry Number.

696663-45-3Relevant academic research and scientific papers

Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity

Pingali, Harikishore,Raval,Raval,Makadia,Zaware,Goel,Suthar,Jain,Patel

experimental part, p. 497 - 502 (2009/04/04)

α-Alkoxy arylpropanoic acids containing 2-phenyloxazole-4yl-alkyl moiety are found to be potent hypolipidemic agents. These compounds were potent activators of the peroxisome proliferator activated receptor γ (PPARγ), with moderate PPARα activity and known to cause adverse effects such as weight gain and edema, which are essentially attributed to PPARγ activation. Although extensive work has been done on the phenylpropanoic acid class of compounds, other phenyl propane derivatives such as alcohols, amines, ethers etc. have not received much attention. In order to develop predominant PPARα agonists as hypolipidemic agents with minor chemical modifications on compound III, we have synthesised few (2S)-ethoxyphenylpropane derivatives containing a 2-phenyl-5-methyloxazole- 4ylalkoxy moiety of the general formula IV and evaluated by PPARα and γ transactivation assay in conjugation with in vivo studies in male Swiss albino mice model. Compounds 3c and 3d showed the desired predominant PPARα activity and excellent tryiglyceride reduction in vivo and were selected as lead compounds for further development as hypolipidemic agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 696663-45-3